Mary T Szela
CIK 1410289 · CEO and President · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$867.6K
Companies
11
Total Filings
77
Lifetime Open-Market Net
-$7.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABSI | Director | 10,100 | $6.80 | $68.7K | $0 | 2 | 2026-06-08 |
| KURA | Director | — | $9.05 | — | $0 | 9 | 2026-06-04 |
| TLSIW | CEO and President | 1,065,215 | $0.75 | $798.9K | $350.7K | 10 | 2026-05-18 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 3 | 2024-06-21 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Director | 0 | $199.92 | $0 | $0 | 4 | 2023-06-16 |
| CHRS | Director | 0 | $1.40 | $0 | -$966.8K | 9 | 2021-01-13 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | — | $5.54 | — | $0 | 3 | 2020-06-22 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Chief Executive Officer | 4,384 | — | — | $0 | 2 | 2017-05-11 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Chief Executive Officer | — | — | — | $0 | 3 | 2016-11-30 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 3 | 2015-08-27 |
| ABBOTT LABORATORIES (ABTw) Delisted | Senior Vice President | 172,123 | — | — | -$7.07M | 27 | 2011-12-16 |
Recent Filings · Page 5 of 8
77 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-01 | — | Grant (A) | — | $0 | |
| 2016-11-30 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Disp (D) | — | $0 | EDGAR |
| 2016-05-26 | CHRS | Grant (A) | — | $0 | EDGAR |
| 2016-05-11 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-11 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-27 | Receptos, Inc. (RCPT) Delisted | Disp (D) | −7,400 | $0 | EDGAR |
| 2015-06-01 | Receptos, Inc. (RCPT) Delisted | Grant (A) | +7,400 | $0 | EDGAR |
| 2015-05-27 | CHRS | Grant (A) | — | $0 | EDGAR |
| 2015-04-03 | CHRS | Grant (A) | — | $0 | EDGAR |
| 2014-07-29 | Receptos, Inc. (RCPT) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.